Bioventus (NASDAQ:BVS – Get Free Report) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its competitors? We will compare Bioventus to similar businesses based on the strength of its valuation, institutional ownership, analyst recommendations, earnings, profitability, dividends and risk.
Valuation and Earnings
This table compares Bioventus and its competitors top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Bioventus | $585.64 million | $22.73 million | 13.81 |
| Bioventus Competitors | $1.88 billion | $139.14 million | 12.53 |
Bioventus’ competitors have higher revenue and earnings than Bioventus. Bioventus is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Analyst Recommendations
This is a breakdown of current ratings and target prices for Bioventus and its competitors, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bioventus | 0 | 1 | 5 | 0 | 2.83 |
| Bioventus Competitors | 4285 | 10564 | 18343 | 830 | 2.46 |
Bioventus currently has a consensus price target of $16.60, suggesting a potential upside of 50.29%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.43%. Given Bioventus’ stronger consensus rating and higher possible upside, research analysts clearly believe Bioventus is more favorable than its competitors.
Profitability
This table compares Bioventus and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bioventus | 9.78% | 26.31% | 10.13% |
| Bioventus Competitors | -276.78% | -149.08% | -21.73% |
Institutional and Insider Ownership
62.9% of Bioventus shares are held by institutional investors. Comparatively, 40.6% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 33.5% of Bioventus shares are held by insiders. Comparatively, 15.0% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Volatility and Risk
Bioventus has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, Bioventus’ competitors have a beta of 2.57, meaning that their average stock price is 157% more volatile than the S&P 500.
Summary
Bioventus beats its competitors on 9 of the 13 factors compared.
Bioventus Company Profile
Bioventus Inc. is a medical technology company focused on helping patients recover from musculoskeletal conditions and injuries. Its products and services support bone healing, pain management and surgical care. The company’s offerings include noninvasive devices that use ultrasound to support bone healing, injectable treatments for osteoarthritis pain, and surgical products such as bone graft materials and ultrasonic instruments used in procedures. Bioventus began operations in 2012, originating from businesses previously owned by Smith & Nephew.
Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.
